Verdú M^a,b,∗, Trias I^a,b,c, Román R^b, Rodón N^b, Pubill C^a, Calvo M^d, Garcia-Pelaez B^b, Diaz O^b, Puig X^a,b,c

^a Histopat Laboratoris, Barcelona, Spain, ^b BIOPAT Biopatologia Molecular, Grup Assistencia, Barcelona, Spain, ^c Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain, ^d Universitat de Barcelona (UB), Departament d’Estadística, Barcelona, Spain

Abstract

The study of epidermal growth factor receptor mutations has become essential for the treatment of lung cancer. The aim of this study was to find a correlation between morphological changes and EGFR mutational […]

Verdu M^1,2, Trias I^1,2,3, Roman R¹, Rodon N¹, Pubill C², Arraiza N², Martinez B², Garcia-Pelaez B¹, Serrano T^1,2,3, Puig X^1,2,3.

¹BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain. ²Histopat Laboratoris, Barcelona, Spain. ³Hospital de Barcelona-SCIAS, Grup Assistència, Barcelona. Spain.

Abstract

The co-expression of HER2 and EGFR L858R in a solitary nodule removed from the lung, whose mutation was not confirmed by molecular techniques, made us think about the possible existence of a cross-reaction between HER2 and the EGFR L858R-specific antibody. Our study was […]

Montse Verdu^1,2, Natalia Rodon², Ruth Roman², Isabel Trias^1,2,3, Carme Pubill¹, Nuria Arraiza¹, Begonya Martinez¹, Beatriz Garcia-Pelaez² and Xavier Puig^1,2,3.

¹Histopat laboratoris, Barcelona, Spain; ²BIOPAT. Biopatolodia Molecular, Grup Assistencia, Barcelona, Spain and ³Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain.

Background: The use of epidermal growth factor receptor (EGFR) mutation-specific antibodies is likely to get soon incorporated into clinical practice due to its proven correlation with the presence of EGFR mutation in lung adenocarcinoma, especially in cases with limited tumor material, or in […]

Ruth Román^1*, Natalia Rodón^1*, Montse Verdú^1,2, Beatriz García-Peláez¹ , Mercè Pujol¹ y Xavier Puig^1,2,3

¹BIOPAT. Biopatologia Molecular, SL, Grup Assistència, Barcelona; ²Histopat Laboratoris, Barcelona; ³Hospital de Barcelona, SCIAS, Grup Assistència, Barcelona.

Introducción:

Las mutaciones en el receptor del factor de crecimiento epidérmico (EGFR) se correlacionan con respuesta a inhibidores del dominio tirosina cinasa (TKIs) y aumento de la supervivencia. La necesidad de establecer con exactitud el estado mutacional de EGFR y el hecho de que en la gran mayoría de casos de cáncer […]